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ABSTRACT 
Functional interplays between different transmitter systems are known to affect 
the signalling of the micturition reflex arc. The functional implications of many 
of these interactions, such as between ATP and acetylcholine, have yet to be 
unravelled. This thesis aimed to identify and characterize the functional 
importance of a proposed atropine-sensitive component in purinergic 
responses. Furthermore, its impact on afferent signalling and changes during 
experimental (cyclophosphamide-induced) cystitis were to be studied in vitro 
and in vivo. 
  
The existence of an atropine-sensitive part of purinergic responses important 
for direct detrusor contractions was proven. Furthermore, this purinergic-
cholinergic link was shown to be dependent on an intact urothelium as well as 
caveolae. This suggests a pronounced interaction between these structures, 
tentatively indicating the caveolae in the urothelium to be of importance for 
the ATP-evoked release of acetylcholine. Blockade of neuronal transmission 
by tetrodotoxin did not affect this release, suggesting it to be non-neuronal. 
Cystitis altered the urothelial signalling, diminishing the purinergic atropine-
sensitivity, showing this link to be important for healthy bladder signalling and 
to be affected during cystitis. Also, atropine significantly decreased 
contractions induced by the stable ATP-analogue α,β-MeATP, demonstrating 
 the P2X-purinoceptors (likely P2X1 and/or P2X3) to be involved in purinergic 
release of acetylcholine in the healthy rat urinary bladder. Notably, in vivo the 
purinergic release of acetylcholine was able to activate the micturition reflex 
arc and trigger afferent signalling. The cholinergic afferent modulation 
depends on the activation of muscarinic receptors of the M2/M4- (inhibitory) 
and M3-subtypes (facilitatory). 
 
Thus, a cholinergic part of purinergic signalling exists in the rat urinary 
bladder, with important function both in vitro (i.e. direct contractile responses) 
and in vivo (i.e. modulation of afferent signalling). Cystitis hinders the 
purinergic-cholinergic signalling in the urothelium, presumably mediated via 
caveolae, showing changes in urothelial signalling to be of outmost importance 
in inflammatory lower urinary tract disorders. These results increase the 
knowledge of healthy bladder signalling and may provide new insights for 
future pharmacotherapies.  
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 Populärvetenskaplig sammanfattning 
Interstitiell cystit och överaktiv blåsa är båda exempel på sjukdomar som 
påverkar de nedre urinvägarna. De karaktäriseras av symtom såsom 
trängningar och ökat behov av att urinera. Patienter med interstitiell cystit lider 
också av smärta från urinblåsan eller kringliggande områden. Dessutom är 
urinblåsan ofta inflammerad vid interstitiell cystit. Inflammation kan påverka 
funktionen av urinblåsans muskulatur, vilket i sin tur kan bidra till 
ovannämnda symptom.  
Urinblåsans muskulatur kan vara avslappnad (relaxerad) som när den lagrar 
urin, eller ihopdragen (kontraherad) som vid tömning av urin. Många olika 
signalsubstanser har visats vara involverade i dessa processer. Särskilt viktig 
vid kontraktion är signalsubstansen acetylkolin som utövar sin effekt genom 
att påverka kolinerga receptorer. Signalsubstansen adenosintrifosfat (ATP) är 
också viktig, särskilt vid vissa sjukdomar (såsom inflammation) och i 
normalfallet i de nerver som skickar signaler till hjärnan då blåsan fylls 
(afferenta nerver). Även andra strukturer i urinblåsan är viktiga för signalering. 
Ett exempel är det innersta cellagret i urinblåsan, urotelet, som både uttrycker 
många olika receptorer och kan frisätta signalsubstanser. Vidare har caveoler 
(inbuktningar på cellers membran) visats vara betydelsefulla. Signaleringen i 
urinblåsan kompliceras ytterligare av att de olika signalsubstanserna kan 
påverka varandra. Detta verkar vara av stor betydelse för normal funktion av 
urinblåsan. Ett sådant samspel där ATP verkar öka frisättningen av acetylkolin 
har identifierats i tidigare studier. 
Huvudmålet med denna avhandling var att undersöka och beskriva möjliga 
funktionella effekter medierade av denna koppling mellan ATP och 
acetylkolin, samt att ta reda på om (och i så fall hur) den förändras vid 
inflammation. I denna avhandling har studier gjorts både på isolerad vävnad 
från urinblåsa (in vitro) och på sövd råtta (in vivo) för att besvara de 
vetenskapliga frågeställningarna. Urinblåsans normala funktion har jämförts 
med den hos råttor som blivit behandlade för att frambringa en lokal 
blåsinflammation.  
Resultaten i avhandlingen visar att ATP kan frisätta acetylkolin i urinblåsan 
genom att stimulera purinerga receptorer, troligen av typen P2X1 och/eller 
P2X3, på urotelet. Denna signalering är beroende av såväl fungerande urotel 
 som caveoler, och visades vara viktig för ATP’s sammandragande effekt på 
blåsmuskulaturen samt dess effekter på afferent nervsignalering. Inflammation 
visades påverka den urotel- och caveol-beroende signaleringen till den grad att 
acetylkolin inte längre frisätts vid stimulering (med ATP) av de purinerga 
receptorerna. Detta visar på betydelsen av ett intakt och välfungerande urotel 
för urinblåsans funktion, vilket förändras vid sjukdom (inflammation).  
Avhandlingen presenterar också en ny roll för acetylkolin i urinblåsans 
signalering då signalsubstansen visades kunna modulera (öka eller minska) 
afferent nervsignalering genom att påverka kolinerga receptorer av typen M3 
respektive M2/M4. Detta är av intresse då många sjukdomar i urinblåsan, 
inklusive interstitiell cystit och överaktiv blåsa, tros bero på en ökad 
signalering från urinblåsan till det centrala nervsystemet. Resultaten visar att 
inte bara ATP, utan också acetylkolin, är viktigt för afferent signalering. 
Vidare studier som undersöker betydelsen av ATP-inducerad acetylkolin-
frisättning i andra sjukdomsmodeller behövs. Det måste även undersökas hur 
väl dessa resultat stämmer med situationen i människa. Avhandlingen 
presenterar ny kunskap om vikten av samspelet mellan dessa olika 
signalsubstanser för urinblåsans funktion i hälsa och hur de förändras vid 
inflammation. Detta kan leda till nya möjliga måltavlor för forskning kring 
läkemedelsbehandling av sjukdomar i de nedre urinvägarna.  
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1 Introduction 
The parasympathetic innervation transmits signals for emptying the bladder 
and acetylcholine is the principal transmitter in this nervous system. However, 
more than a 100 years ago, it was observed that a large part of these 
parasympathetic responses are resistant to the muscarinic antagonist atropine 
and thus dependent on other transmitters as well. Over the years to come efforts 
were made in order to identify the compounds responsible for these non-
adrenergic, non-cholinergic (NANC) responses. Eventually, in the 1970’s, 
ATP was established to be a co-transmitter in the parasympathetic nervous 
system. During the following decades, the existence of any NANC-
transmission in the human urinary bladder was much debated. However, the 
knowledge regarding the roles of ATP in the micturition reflex arc has been 
broadened by more recent findings, namely that ATP has important functions 
in the initiation of the micturition reflex arc. The importance of ATP is also 
made evident by its altered functions during pathological conditions in man. 
In this thesis, the origin and functional importance of NANC-transmission in 
the rat urinary bladder is studied. The meaning of NANC-signalling is also 
examined in a new perspective, where the interactions between acetylcholine 
and ATP may occur at other sites as well, rather than in the parasympathetic 
junction. 1.1 Anatomy of the urinary bladder 
The urinary bladder is an expandable organ situated in the lower abdomen with 
the main purpose of storing and eliminating urine. Urine enters the bladder via 
the two ureters, situated dorsally, which constitute the base of a triangular area 
called the trigone. The top of the inverted triangle is formed by the inner 
urethral orifice of the urethra, located at the inferior part of the bladder base. 
At the end of the urethra an outer urethral sphincter is located which, unlike 
the rest of the bladder, consists of striated skeletal muscle and is voluntarily 
controlled. The bladder wall consists of an inner uroepithelial coating (the 
urothelium), a suburothelial layer, often called the lamina propria, a smooth 
muscle layer (detrusor muscle) and an outer layer of fibrous connective tissue 
known as the adventitia or serosal layer. The detrusor smooth muscle in both 
humans and rats consists of an inner and outer longitudinal muscle layer and a 
circular layer between. When empty the bladder wall is folded into rugae, 
wrinkles that allow the bladder to stretch in order to accommodate larger 
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amounts of urine. At a certain threshold, stretch-induced afferent signals are 
triggered relaying the need for voiding (see section: 1.2). A median excreted 
volume in humans has been estimated to be around 330 ml (Fitzgerald et al., 
2002). 1.1.1 The urothelium  
The innermost cell layers of the bladder wall constitute the transitional 
epithelium of the bladder called the urothelium. The urothelium consists of 
three different cell types, the umbrella cells, the intermediate cells and the basal 
cells. (Jost et al., 1989). The superficial umbrella cells form an important 
barrier between the urine and the rest of the body through tight junctions, apical 
uroplakins and the protective mucus-like glucose-amino-glycan layer (GAG-
layer) (Hu et al., 2000; Varley et al., 2006). 
The urothelium is today known not only to function as a passive barrier against 
harmful substances but also to be a sensory organ, expressing various receptor 
subtypes (Merrill et al., 2016). Furthermore, transmitter substances such as 
adenosine 5’-triphosphate (ATP), acetylcholine and nitric oxide (NO) may be 
released from the urothelium (Birder et al., 1998; Ferguson et al., 1997). This 
may stimulate afferent or efferent nerve fibres, trigger smooth muscle 
contraction and have paracrine effects on the urothelium and/or suburothelium. 
During inflammation the urothelial release of NANC-substances, primarily 
ATP and NO, is increased which might sensitize the afferent nerve fibres with 
urinary frequency and sensations of pain as a result (Andersson et al., 2008; 
Mansfield & Hughes, 2014; Vesela et al., 2012).  1.1.2 Caveolae  
Caveolae are cholesterol rich membrane invaginations that are expressed in 
most mammalian cells. Since their discovery in the 1950s, the caveolae have 
been assigned various abilities including exocytosis, endocytosis and signal 
transduction (Cohen et al., 2004; Palade, 1955; Parton & Simons, 2007). 
Research has shown that a large variety of receptors can be expressed in, or 
translocated to, these structures; thus the caveolae mediated signal transduction 
may be important for bladder contraction (Li et al., 1995; Lisanti et al., 1994; 
Shaul & Anderson, 1998). Furthermore, the caveolae have been shown to be 
involved in urinary bladder disorders such as overactive bladder, bladder 
hypertrophy and bladder cancer (Cohen et al., 2004; Cristofaro et al., 2012; Fu 
Johanna Stenqvist 
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et al., 2017). A study from 2012 showed a decrease of the caveolae specific 
protein caveolin-1 in cyclophosphamide-induced (CYP-induced) cystitis (Kim 
et al., 2012). However, functional studies are missing.  1.2 Physiology of the urinary bladder 
The micturition cycle in man can be divided into two separate phases; the 
filling of the bladder/urine storage and the excretion of urine/micturition 
respectively. During filling, the sympathetic branch of the autonomic nervous 
system (ANS) is dominant. These nerves exit the spinal cord at the thoraco-
lumbar level (T10-L2). The sympathetic hypogastric nerve reaches the bladder 
via the inferior mesenteric ganglion, some sympathetic nerves also reach the 
bladder via the paravertebral sympathetic chain ganglia and the pelvic nerves 
(De Groat & Ryall, 1969; de Groat et al., 2015; Fehér et al., 1980; Langley & 
Anderson, 1895). The sympathetic neurotransmitter norepinephrine (NE) 
stimulates β-adrenergic receptors (mainly of the β3-subtype) on the detrusor 
muscle resulting in relaxation of the bladder wall promoting bladder 
compliance (Abdel-Rahman et al., 1983; Elmér, 1974). Furthermore, NE 
stimulates contraction of the internal urethral sphincter and bladder neck via 
α1-adrenoceptors, counteracting leakage of urine during the storage phase 
(Caine et al., 1975; Chang et al., 2000).  
During bladder filling the release of acetylcholine from the pudendal nerve 
endings (arising from motor neurons in the S2-S4 segments of the spinal cord) 
promotes contraction of the external urethral sphincter through the stimulation 
of cholinergic nicotinic receptors. As the bladder fills, a certain threshold level 
is eventually reached where stretch-sensitive receptors in the urothelium have 
been suggested to activate, triggering the release of neurotransmitters such as 
ATP (Birder et al., 2005; Ferguson et al., 1997; Ishihama et al., 2006). 
Urothelially derived neurotransmitters may alter afferent firing, however there 
are also mechanoreceptors expressed directly on afferent nerve endings 
(Häbler et al., 1993a; Häbler et al., 1993b).  
Two types of afferents are present in the bladder, namely myelinated Aδ- and 
unmyelinated C-fibres (Fowler et al., 2008; Häbler et al., 1990; Satchell & 
Vaughan, 1994). In the rat the micturition reflex is mainly triggered by Aδ-
fibres (Mallory et al., 1989). C-fibres may have a more prominent role during 
various pathological conditions in the bladder as they generally respond to 
noxious and nociceptive stimuli for instance during inflammation (Fowler et 
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al., 2008). Afferent signals are transmitted through the spinal cord via neurons 
that project to the periaqueductal grey (PAG) (Gable & Kingsley, 1996). The 
PAG transmit signals to the pontine micturition center (PMC) which in turn 
sends efferent signals through the spinal cord back to the bladder, inhibiting 
sympathetic control and promoting the parasympathetic activity (Gable & 
Kingsley, 1996; Noto et al., 1989). Higher brain centres suggested to be 
involved in the micturition reflex arc, affecting the PAG activity and thereby 
the PMC excitation, include for example the prefrontal cortex, the 
hypothalamus and the bed nucleus of the stria terminalis (Fowler et al., 2008). 
During the micturition phase, the parasympathetic branch of the ANS is 
dominant. These nerves exit the spinal cord at the sacral region (S2-S4). The 
parasympathetic pelvic nerve reaches the bladder through the pelvic plexus and 
ganglia. In female rats the ganglion is situated between the uterus and cervix, 
whereas the larger ganglion in male rats is situated close to the prostate 
(Gabella, 2004). The parasympathetic transmitter acetylcholine stimulates 
contraction of the bladder wall mainly via the activation of muscarinic M3-
receptors, but stimulation of M2-receptors has also been suggested to indirectly 
enable bladder contraction (see section: 1.3). At the same time, ATP and NO 
contribute to contraction of the bladder wall, and relaxation of the bladder 
neck/urethra respectively, enabling voiding when suitable (Andersson et al., 
1991; Aronsson et al., 2010; Persson & Andersson, 1994).  1.3 Signal transduction 
The autonomic regulation of the urinary bladder, leading to contraction or 
relaxation of the detrusor smooth muscle, is controlled by the efferent release 
of transmitter substances from the pelvic and the hypogastric nerve 
respectively. Contraction is mainly mediated via the release of acetylcholine, 
acting on muscarinic receptors, and ATP acting on purinoceptors. To which 
extent the different transmitters are contributing to contraction seems to be 
species specific with a minor purinergic involvement in the human bladder 
(under non-pathological conditions) whereas the two transmitters are, under 
certain circumstances, equally responsible for the contractile response of the 
rat bladder (Burnstock, 1976; Burnstock, 2009; Kinder & Mundy, 1985; 
Yoshida et al., 2001). However, during pathological conditions, such as 
bladder pain syndrome/interstitial cystitis (BPS/IC), ATP seems to have a 
larger role in bladder signalling (Palea et al., 1993). For instance, urothelial 
P2X3-purinoceptors are upregulated during this condition (Sun & Chai, 2004). 
Johanna Stenqvist 
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Relaxation of the bladder wall is largely controlled by the release of NE, acting 
on adrenergic receptors.  1.3.1 Cholinergic signalling 
Acetylcholine was discovered during the early 1900s and was the first 
acknowledged neurotransmitter. In 1936, the Nobel Prize in physiology or 
medicine was awarded to Sir Henry Hallett Dale and Otto Loewi for their 
respective discoveries leading to the identification of acetylcholine as a 
neurotransmitter. Dale was, in 1914, able to extract acetylcholine from 
Claviceps purpurea ergot, and examined its effect as a pharmacological 
substance (Dale, 1914; Ewins, 1914). In 1921, Loewi discovered a substance 
released from the vagal nerve in frogs, which he named “Vagusstoff” (Loewi, 
1921). The substance mediated a decrease in heart rate and later turned out to 
be acetylcholine. 
Two acetylcholine synthesizing enzymes exists, called choline-
acetyltransferase (ChAT) and carnitine-acetyltransferase (CarAT), that 
convert choline and acetyl coenzyme A to acetylcholine in some cell types. 
ChAT is mainly responsible for the synthesis of acetylcholine in the neurons 
whereas the mitochondrial CarAT seems to be responsible for the non-
neuronal synthesis of acetylcholine (Ekstrom & Elmer, 1977; Hanna-Mitchell 
et al., 2007; Yoshida et al., 2008). In the neurons, acetylcholine is stored in 
vesicles and the vesicular acetylcholine transporter (VAChT) is responsible for 
the uptake of the transmitter into vesicles, the subsequent release of 
acetylcholine is mediated by calcium-dependent exocytosis (Carroll & 
Goldberg, 1975; Weihe et al., 1996).  
The release of acetylcholine from urothelial cells (non-neuronal cells) does not 
appear to involve vesicular uptake and exocytosis and VAChT is not expressed 
in these cells (Hanna-Mitchell et al., 2007). Furthermore, studies using 
Brefeldin (an inhibitor of vesicle formation) did not show any significant effect 
on the release of acetylcholine (Hanna-Mitchell et al., 2007; Lips et al., 2005). 
However, the polyspecific organic cation transporter (OCT), more specifically 
of the OCT3-subtype, has been found in urothelial cells and appears to be 
involved in the urothelial release of acetylcholine (Hanna-Mitchell et al., 
2007). The breakdown of acetylcholine is mediated by the enzymes 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) that converts 
acetylcholine to choline and acetate (Colović et al., 2013; Darvesh et al., 2003; 
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Silman & Sussman, 2008). Reuptake of the choline is mediated by the choline 
transporter (Kuhar & Murrin, 1978).  
1.3.1.1 Muscarinic	receptors	
Acetylcholine activates two kind of receptors, muscarinic and nicotinic 
receptors; however, the muscarinic receptors are the most important subtype 
for contraction of the bladder wall. There are five different muscarinic 
receptors (M1-M5), all of which are guanine nucleotide-binding protein (G-
protein) coupled receptors (Eglen et al., 1996). The G-proteins can be divided 
into subgroups called Gs, Gq, G12 and Gi/o (T Gudermann et al., 1996). The 
M1-, M3- and M5-receptors are excitatory Gq/11-coupled receptors and lead to 
the activation of phospholipase C (PLC) and a subsequent increase in calcium 
via the activation of inositol 1,4,5-triphosphate and diacylglycerol (Wu et al., 
2000). The stimulation of the M2- and M4-receptors, considered to be 
inhibitory Gi/o-coupled receptors, inactivates adenylyl cyclase and prolongs the 
opening of various ion channels (e.g. potassium) (van Koppen & Kaiser, 2003; 
Zholos  et al., 2004).  
All five subtypes have been identified in both the human and rat urinary 
bladder (Tyagi et al., 2006). However, studies have shown the numerically 
predominating muscarinic receptor to be of the M2 subtype, followed by the 
M3 subtype in a ratio 3:1 (Goepel et al., 1998). This seems to be the case for 
other species as well (Hegde & Eglen, 1999; Wang et al., 1995; Yamanishi et 
al., 2000). The muscarinic receptor subtype consistently reported, and widely 
accepted, as the one most important for generating contraction of the detrusor 
smooth muscle is the M3-receptor (Hegde et al., 1997; Tobin, 1995; Tobin & 
Sjogren, 1995). However, the M2-receptor may be indirectly involved in the 
contractile response of the bladder wall through the inhibition of adenylyl 
cyclase (mentioned above) which in turn hinders relaxations of the detrusor 
muscle using this pathway (e.g. β-adrenergic receptors and P1-purinoceptors) 
(Giglio et al., 2001; Ma et al., 2002).  
Muscarinic autoreceptors are also expressed on efferent neurons in form of 
inhibitory M2- or M4-receptors and facilitatory M1-receptors in both rats and 
humans (D'Agostino et al., 2000; Somogyi & de Groat, 1999; Somogyi et al., 
1994; Tobin & Sjogren, 1995). Studies in mice have revealed the expression 
of the M2-, M3- and M4-receptors on afferent nerve fibres in the urinary bladder 
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(Nandigama et al., 2010). Furthermore, stimulation of muscarinic receptors 
appears to affect the C-fibre afferents (Kullmann et al., 2008). 
All five receptor subtypes are also expressed on the bladder urothelium 
(Bschleipfer et al., 2007; Tyagi et al., 2006). Some of these receptors may also 
be expressed in the lamina propria on the interstitial cells of Cajal (Grol et al., 
2009). 1.3.2 Purinergic signalling 
Although the phenomenon of atropine-resistant bladder signalling has been 
described as early as 1895 (Langley & Anderson, 1895), the identification of 
the non-adrenergic-, non-cholinergic-, (NANC) transmitters mainly involved 
was not clarified until much later. In the beginning of the 70’s Burnstock et al. 
introduced the concepts of purinergic neurotransmission as well as purinergic 
co-transmission (Burnstock, 1972; Burnstock, 1976). Many candidate 
substances responsible for the atropine-resistant bladder responses were tested 
and finally, in 1978, ATP was identified as the main NANC-transmitter 
involved in the parasympathetic neurotransmission in the guinea pig urinary 
bladder (Burnstock et al., 1978). This challenged the previous definition of 
neurotransmission, “Dale’s Principle”, which for a long time was interpreted 
in a way suggesting that only one type of transmitter could be released from a 
specific nerve cell (Dale, 1935; Eccles et al., 1954). Today, ATP is an 
established co-transmitter in almost all nerve types and is co-released with a 
large variety of neurotransmitters including acetylcholine, NE and dopamine 
(Banks et al., 2006; Burnstock, 2009; Silinsky, 1975). 
ATP can be synthesized in three different ways; during glycolysis, the Krebs 
cycle and by mitochondrial oxidative phosphorylation. The formation of 
neuronal ATP is mainly through mitochondrial oxidative phosphorylation and 
is dependent on the availability of adenosine 5’-diphosphate (ADP) and/or 
adenosine 5’-monophosphate (AMP). Purines are produced by de novo 
biosynthesis in the cells but also through the re-uptake of purines (e.g. 
adenosine) from the extracellular matrix which can, after conversion to ADP, 
be used in oxidative phosphorylation. Vesicular uptake, by vesicular 
nucleotide transporters (VNUT), and vesicular storage of ATP have been 
shown previously (Gualix et al., 1999; Moriyama et al., 2017; Novak, 2003). 
The release of acetylcholine is calcium-dependent and subsequent exocytosis 
has been suggested (Pankratov et al., 2007; Pintor et al., 1992). Similarly, 
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urothelial release of ATP (e.g. stretch-induced release) partly consists of 
VNUT dependent exocytosis (Nakagomi et al., 2016). However, other proteins 
have also been shown to be involved in the release of ATP, for example 
pannexin hemi channels (or connexion), P2X7-purinoceptors and maxi-ion 
channels (Dahl, 2015; Lazarowski et al., 2011). 
After dissociation from the receptor protein, the metabolism of ATP may 
involve a variety of different proteins. Ecto-nucleoside triphosphate 
diphosphohydrolases and ecto-nucleotide pyrophosphatase/ 
phosphodiesterases are able to transform ATP to ADP and/or ADP to AMP. 
AMP may be further metabolized by ecto-5´-nucleotidases (CD73) to 
adenosine (Yegutkin, 2008; Zimmermann, 1996; Zimmermann, 2000; 
Zimmermann et al., 2012). Finally, adenosine may be metabolized to inosine 
by a range of proteins, for instance adenosine deaminase (Cristalli et al., 2001). 
There are also alkaline phosphatases which may metabolize both ATP, ADP 
and AMP (Zimmermann, 2000). 
1.3.2.1 Purinoceptors	
The purinoceptors are divided into two sub-families, the receptors activated by 
adenosine belong to the P1-purinoceptors whereas the receptors activated by 
ATP/ADP belong to the P2-purinoceptors (Burnstock, 1978). The P2-
purinoceptros are further separated into two different groups called P2X- and 
P2Y-purinoceptors (Burnstock & Kennedy, 1985). There are four different P1-
purinoceptors (A1, A2A, A2B and A3) all of which are G-protein-coupled and 
seem to mainly affect adenylyl cyclase and hence the levels of cAMP 
(Abbracchio & Burnstock, 1994). Seven subtypes of P2X-purinoceptors exist 
(P2X1-P2X7), that are ligand gated ion channels permeable to cations such as 
calcium and sodium (Valera et al., 1994). Furthermore, they are expressed as 
hetero- or homomers (Coddou et al., 2011). The P2Y-purinoceptors are, like 
the P1-purinoceptors, G-protein-coupled and affect either PLC or adenylyl 
cyclase via their Gs-, Gi/0- or Gq/11-protein (Erb & Weisman, 2012). Currently 
eight different P2Y-purinoceptors have been identified (P2Y1, P2Y2, P2Y4, 
P2Y6 and P2Y11-P2Y14). Some of the P2Y-purinoceptors are not only activated 
by ATP/ADP but can also be activated by uridine 5’-triphospate (UTP) or 
uridine 5’-diphospate (UDP) (Nicholas et al., 1996). 
All seven P2X-purinoceptors have been identified by immunohistochemistry 
or RT-PCR in the rat and human urinary bladder (Creed et al., 2010; Moore et 
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al., 2001). However, conflicting evidence exist. For instance Creed et al. 
reported the P2X3- and P2X6-purinoceptors to be exclusively expressed in the 
male rat bladder and a study from O’Reilly et al. reported no RNA expression 
of these purinoceptors in the human bladder (Creed et al., 2010; O'Reilly et al., 
2001). P2X1 is consistently reported as the most abundant purinoceptor in the 
detrusor smooth muscle in these studies and is considered to be the subtype 
mainly responsible for detrusor contraction (Aronsson et al., 2010). 
Involvement of the P2X3-purinoceptor in the contractile response has also 
been suggested (King et al., 2004). 
P2X-purinoceptors have also been detected in the urothelium of many species 
including man, however some species differences appears to exist (Birder & 
Andersson, 2013; Elneil et al., 2001; Shabir et al., 2013). For instance, all seven 
P2X-purinoceptors have been found in the cat urothelium, while a recent study 
of primary mouse urothelial cells shows the expression of the P2X1-P2X6-
purinoceptors but not P2X7 (Birder et al., 2004; Chess-Williams et al., 2019). 
However, P2X7 has been shown in the urothelium of rats (Lee et al., 2000). 
Various P2Y-purinoceptors have been detected in the urothelium as well, 
including the P2Y1-, P2Y2-, P2Y4- and P2Y11-subtypes (Birder et al., 2004; 
Chopra et al., 2008; Shabir et al., 2013). Studies also suggest occurrence of 
P2Y6-purinoceptors in the urothelium (Timóteo et al., 2014).  
The expression of all seven P2X-purinoceptors and P2Y1, P2Y2 and P2Y4 has 
been shown on bladder afferent nerves (Chen & Gebhart, 2010; Ruan et al., 
2005; Xiang et al., 1998), with the P2X2- (and/or P2X2/3-) and P2X3-
purinoceptors having a demonstrated functional importance (Cockayne et al., 
2005; Cockayne et al., 2000). However, contradictive results regarding these 
findings exist as well (Takezawa et al., 2016). Among the P2Y-purinoceptors, 
the P2Y2-subtype has been proposed as a functionally important subtype in 
afferent signalling (Chen et al., 2010). All P1-purinoceptor subtypes have been 
detected in the rat and human urinary bladder (Dixon et al., 1996; Yu et al., 
2006), with the P1A1-purinoceptor seemingly the one mainly responsible for 
purinergic efferent modulation (Acevedo et al., 1992; Ikeda et al., 2012).  1.3.3 Relaxatory pathways 
Norepinephrine (NE), discovered in the early 20th century, is the main 
transmitter of the sympathetic nervous system (Ahlquist, 1948; Dale, 1913). 
There are two groups of adrenoceptors, the α- and β-adrenergic receptors. The 
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α-adrenergic receptors are further divided into α1 and α2 subtypes, where there 
are three different α1-adrenoceptors (α1A, α1B and α1D) and three different α2-
adrenoceptors (α2A, α2B and α2C). The β-adrenoceptors are subdivided into β1, 
β2 and β3. All adrenergic receptors are G-protein coupled receptors blocking or 
activating adenylyl cyclase (α2 and β1-β3 respectively) or activating PLC (α1) 
(Molinoff, 1984). All adrenoceptor subtypes have been identified in the human 
and rat bladder (Levin et al., 1988; Nomiya & Yamaguchi, 2003). Some α- and 
all three β-adrenergic receptors have also been detected in the urothelium 
(Ishihama et al., 2006; Otsuka et al., 2008; Walden et al., 1997). 
In the urinary bladder, the sympathetic nervous system is important during the 
filling phase where NE mediates relaxation of the bladder wall mainly via β-
adrenoceptors (Abdel-Rahman et al., 1983; Elmér, 1974). Both β2 and β3 are 
important for bladder relaxation in the rat (Oshita et al., 1997), whereas in 
humans the β3-subtype is, to a larger degree, responsible for the relaxation 
(Igawa et al., 1998). Sympathetic efferent transmission stimulates the 
contraction of the urethra and bladder neck via α1-adrenoceptors (Caine et al., 
1975; Chang et al., 2000).  
Another important neurotransmitter usually considered to be involved in 
relaxatory responses is the non-adrenergic non-cholinergic substance NO. In 
1980, Furchgott et al. identified an endothelium-derived relaxatory factor 
(EDRF) in arterial smooth muscle, which were later determined to be NO 
(Furchgott & Zawadzki, 1980; Palmer et al., 1987). As its main mechanism of 
action, NO is proposed to activate guanylyl cyclase, resulting in increased 
levels of cGMP. The elevated levels of cGMP in turn activate protein-kinases 
involved in smooth muscle relaxation (Bredt & Snyder, 1992). 
In the urinary bladder, NO released from parasympathetic nerves mediates 
relaxation of the bladder neck and urethra and may thus be an important player 
in disorders such as bladder outlet obstruction (BOO) (Andersson et al., 1991; 
Persson & Andersson, 1994). However, NO also affects both the detrusor 
smooth muscle and afferent nerve fibres (Ozawa et al., 1999; Yoshimura et al., 
2001) and may play a role in the development of cystitis (Aronsson et al., 
2014b). Another source of NO in the bladder is the urothelium, mainly released 
upon activation of adrenergic receptors (Birder et al., 1998; Winder et al., 
2017). Furthermore, stimulation of urothelial muscarinic receptors has been 
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shown to mediate urothelial release of NO, primarily in a state of inflammation 
(Andersson et al., 2008).  1.4 Purinergic interactions and the concept of atropine resistance 
Interactions, or crosstalk, between various transmitter systems are important 
features in the micturition reflex arc. As an example, NE may affect the 
efferent release of acetylcholine via prejunctional modulation and vice versa 
(Somogyi et al., 1995). Purinergic interactions also exist where recent findings 
suggest adenosine able to act as an inhibitory modulator on neuronal 
acetylcholine release (Searl et al., 2016; Silva-Ramos et al., 2015). 
Furthermore, acetylcholine may trigger the release of urothelial ATP which 
seems to be increased during IC (Birder et al., 2004). 
ATP is commonly described as one of the NANC-transmitters responsible for 
atropine resistant excitatory responses in the urinary bladder of most species 
(Husted et al., 1980; Levin et al., 1986; Tong et al., 1997). Although other 
neurotransmitters such as tachykinins, vasoactive intestinal peptide (VIP) and 
substance P have been identified in functional NANC-signalling in the urinary 
bladder, the majority of the response is usually accredited to ATP (Levin et al., 
1986; Meini & Maggi, 1994; Moro & Chess-Williams, 2012). In favour of this 
assumption, studies in the rabbit bladder revealed the ATP-induced urinary 
expulsion to be of similar magnitude as that of electrical stimulation in the 
presence of atropine (Levin et al., 1986). However, it is possible that ATP is 
not solely responsible for the NANC contractile responses (Meini & Maggi, 
1994; Moro & Chess-Williams, 2012), a theory put forward by Beznak stating 
that the observed muscle contractions to ATP may be involving acetylcholine 
(Beznak, 1951). This theory was however, more or less, disregarded as the 
evidences for direct ATP-induced contractions were presented, although some 
later findings have been made in support of this idea (Sjogren & Andersson, 
1979).  
The urothelium is an important structure for neurotransmitter interactions as it 
expresses a large variety of receptors and may upon stimulation release various 
transmitters (Winder et al., 2014). Hanna-Mitchell et al. demonstrated ATP to 
be able to stimulate the release of acetylcholine from urothelial cells (Hanna-
Mitchell et al., 2007). However, the plausible functional roles of this ATP-
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induced release of urothelial acetylcholine in the micturition reflex arc or 
directly on the detrusor muscle have not been examined. 1.5 Overactive bladder syndrome 
Overactive bladder syndrome (OAB) is a chronic bladder disorder 
characterized by urgency, often in combination with other lower urinary tract 
symptoms (LUTS) such as nocturia and increased frequency (Haylen et al., 
2010). Some patients have a combination of urgency and urge incontinence, 
referred to as OABWET (Haylen et al., 2010). In order to diagnose OAB other 
medical conditions affecting the lower urinary tract such as urinary tract 
infection and urinary stress incontinence need to be ruled out.  
The prevalence of OAB has been estimated to 16.5 % in the USA (the NOBLE-
study) and to 11.8 % in the EPIC-study, conducted in Canada, Germany, Italy, 
Sweden and United Kingdom (Irwin et al., 2006; Stewart et al., 2003). 
Furthermore, these studies reported an equal prevalence between men and 
women as well as an increased prevalence with age. The pathophysiology of 
OAB is not yet unravelled and may vary between individuals. However, 
theories regarding the pathophysiology of the observed overactivity in these 
patients have emerged and include for instance sensitization of bladder 
afferents and/or increased spontaneous contractions (Brading, 2006; de Groat, 
1997). Recent research also highlights the plausible importance of the bladder 
microbiota and chronic urinary tract infection in the development of OAB 
symptoms (Contreras-Sanz et al., 2016; Drake et al., 2017). Furthermore, an 
altered urothelial signalling has been observed in OAB patients, for instance 
patients suffering from OAB as well as BPS/IC show an increase in the stretch-
induced release of ATP (Contreras-Sanz et al., 2016; Sun et al., 2001). 
Because of the unknown pathophysiology, the pharmacological treatment of 
OAB today is symptomatic in nature and anticholinergics, such as oxybutynin 
and tolterodine, are most commonly prescribed (Robinson & Cardozo, 2012). 
However, due to common side effects, such as dry mouth and constipation, or 
insufficient effect the discontinuation of anticholinergic treatment for OAB 
patients is relatively high (Peeker et al., 2010; Sexton et al., 2011). If 
anticholinergics do not result in clinical improvement or cannot be tolerated 
due to side effects, other available treatment options are e.g. botulinum toxin 
and the β3-adrenoceptor agonist mirabegron (Gormley et al., 2012; Lawrence 
et al., 2010; Leron et al., 2018).  
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1.6 Bladder pain syndrome/interstitial cystitis 
BPS/IC is a chronic bladder disorder often associated with a lowered quality 
of life and sometimes depression (Hanno et al., 2015). BPS/IC is typically 
characterized by pelvic pain in combination with various LUTS including 
frequency, decreased storage capacity and nocturia (Bogart et al., 2007). The 
diagnosis is obtained after ruling out differential diagnoses such as urinary tract 
infection and OAB (Doggweiler et al., 2017; Hanno et al., 2015).  
The reported prevalence of BPS/IC is somewhat inconsistent, with studies 
reporting results ranging between 0.45 – 11.20 % in various cohorts (Leppilahti 
et al., 2002; Lifford & Curhan, 2009). However, BPS/IC appears to be more 
common among the female population and the prevalence increases with age 
(Clemens et al., 2005).  
Despite much scientific effort, the aetiology of BPS/IC is not yet fully 
unravelled but a hypersensitivity of afferents or an upregulation of the 
mechanoreceptor function appear to play a major role. For instance, preclinical 
studies using an in situ half bladder model, enabling investigations of the 
efferent- and afferent-induced responses of the detrusor muscle, showed that 
the reflex-evoked responses are increased during CYP-induced cystitis 
(Aronsson et al., 2014a; Aronsson et al., 2015). This may involve sensitization 
of the afferent neurons and an upregulation of the mechanoreceptor function.  
Furthermore, alterations of the afferent nerve signalling have been widely 
discussed in the development of cyclophosphamide induced cystitis, for 
instance the expression of purinergic P2X-purinoceptors on afferent neurons 
is increased (Dang et al., 2008; Nazif et al., 2007). Likewise, in BPS/IC-
patients, the afferent pathway seems to be sensitized likely resulting in 
symptoms such as frequency and decreased volume voided (Contreras-Sanz et 
al., 2016; Kumar et al., 2010; Sun et al., 2001). Possible explanations include 
infection, autoimmune reactions and alterations in neuronal function (Rourke 
et al., 2014). However, the underlying mechanisms for this disorder remain 
unknown. 
Among the most validated theories for the pathophysiology behind BPS/IC is 
the adherence theory which suggests disturbances in the glucose-amino-glucan 
layer (GAG-layer) of the urothelial epithelium and the subsequent increased 
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permeability for substances such as potassium to be a major cause of LUTS 
associated with this disease (Lilly & Parsons, 1990; Parsons, 2007). 
Furthermore, studies of patients suffering from BPS/IC show changes in 
urothelial integrity and an altered expression of tight junction proteins (Hurst 
et al., 2015; Liu et al., 2012). The increased influx of various substances 
observed may lead to inflammation, which has been shown to affect 
neurotransmitters released from the urothelium as well as sensitizing the 
afferent nerve endings (Kumar et al., 2010; Vesela et al., 2012). However, it is 
also possible that the urothelial permeability is a result of inflammation and 
not the other way around (Chiang et al., 2000).  
The only oral treatment for BPS/IC approved by the American food and drug 
administration (FDA) is called Elmiron® and consists of pentosane 
polysulphates thought to imitate the GAG-layer and thus may protect the 
urothelium to some extent (Hanno, 1997; Waters et al., 2000). Other treatments 
involve amitriptyline, cyclosporine A, transurethral resection of ulcers and 
bladder distension (Hanno et al., 2015). However, there is no cure for BPS/IC 
and further scientific effort is needed to fully understand the aetiology of the 
disorder with the aim to optimize the treatment.  
Although ATP-mediated stimulation directly on the detrusor muscle is 
considered a minor contributor for healthy bladder contraction in humans, the 
initiation of the micturition reflex via afferent nerve endings may be mediated 
by stretch-induced release of ATP from the transitional epithelium (Kanai, 
2011). Furthermore, the role of ATP during pathological bladder disorders is 
markedly increased (Palea et al., 1993; Sjogren et al., 1982). For instance, the 
stretch-induced release of urothelial ATP is elevated in patients suffering from 
BPS/IC and OAB alike, which may affect the sensory nerves, previously 
observed in rat models (Contreras-Sanz et al., 2016; Smith et al., 2005; Sun et 
al., 2001).  
An altered expression of purinergic receptors is observed during both 
disorders. For instance the P2X3-subtype is upregulated in the urothelium of 
patients suffering from BPS/IC or OAB (Sun & Chai, 2004). Preclinically, 
immunohistological stainings of bladders from cats with feline interstitial 
cystitis showed the expression of the P2X1-purinoceptor to be reduced (Birder 
et al., 2004). An altered expression of muscarinic receptors as well as an 
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augmented release of acetylcholine have also been identified (Giglio et al., 
2005; McDermott et al., 2013). For instance in rat models of experimentally 
induced cystitis the expression of muscarinic M5-receptors was shown to be 
upregulated (Giglio et al., 2005). Furthermore, during inflammation of the 
bladder the cholinergic contractile responses are generally decreased (Giglio 
et al., 2005; Mok et al., 2000). The purinergic transmitter system appears to be 
involved also in the development of bladder inflammation and pain (Aronsson 
et al., 2012; Cockayne et al., 2000).  1.7 Experimental cystitis  
Treatment with the alkylating antineoplastic agent cyclophosphamide (CYP) 
has adverse effects in patients including a local haemorrhagic cystitis. This 
knowledge has led to CYP-induced cystitis being a commonly used 
experimental model for studying BPS/IC in rodents. CYP induced cystitis 
shares many characteristics with BPS/IC making it a valid model for studying 
bladder disorders with an inflammatory pathophysiology (Auge et al., 2013; 
Juszczak et al., 2007). It is not yet fully unravelled how CYP induces bladder 
inflammation but research has shown the toxic metabolite acrolein to be 
involved (Cox, 1979). Acrolein has toxic effects on the urothelium eventually 
leading to a local inflammatory response; therefore, patients treated with CYP 
are often prescribed the antioxidant Mesna, which incapacitates acrolein and 
thus alleviates the adverse effects (Haselberger & Schwinghammer, 1995; 
Luce & Simons, 1988).  
Besides CYP-induced cystitis, other models for experimental cystitis exist, all 
of which have their own advantages and disadvantages. These models include 
spontaneous feline interstitial cystitis, neurogenic inflammation (induced by 
e.g. electrical nerve stimulation or antigens such as ovalbumin) and bacterial 
cystitis such as lipopolysaccharide-induced cystitis (LPS-induced cystitis) 
(Bjorling et al., 2011; Jerde et al., 2000; Kowalski et al., 1990; Saban et al., 
1991). 
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1.8 Aims 
The general aims of this thesis were to examine purinergic and cholinergic 
interactions within the micturition reflex and to identify reflex levels and 
structures of importance for the interplay. Furthermore, the possible functional 
implications that this interplay may have on the different levels of the 
micturition reflex arc were characterized. 1.8.1 Specific aims 
In the in vivo and in vitro experiments the following research issues were 
addressed:  
 How much of the ATP-induced bladder contraction depends on 
cholinergic effects? 
 Does the interplay take place within the urothelium or at the neuronal 
level involving afferents and/or efferents? 
 Is the interplay affected by inflammation and/or by disruption of 
caveolae? 
 Which purinoceptors are involved? 
 Do the interactions occur in vivo or only in isolated tissue? 
An in vitro whole bladder setup, enabling the administration of substances to 
the luminal or adventitial side of the bladder wall, was employed in order to 
determine if the ATP-evoked release of acetylcholine was site-specific (paper 
I). The origin of the ATP-induced release of acetylcholine was further 
elucidated by the denudation of the urothelium (paper I, II and IV). 
Furthermore, the functional interplay between ATP and acetylcholine was 
examined in CYP-pre-treated animals and compared to healthy controls in 
order to establish possible impacts of inflammation on this signalling 
interaction (paper I and II). 
The caveolae are important signalling platforms and their involvement in 
healthy bladder signalling as well as possible alterations during CYP-induced 
cystitis were unravelled in paper II. Furthermore, the importance of caveolae 
for the ATP-evoked release of acetylcholine and possible interactions with the 
urothelium was examined. 
The functional interplay between ATP and acetylcholine was further 
characterized in paper III, which aimed to elucidate the receptors involved in 
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this interaction by the application of various purinergic agonists and 
antagonists in vitro. In this paper, the possible involvement of the urothelium 
and/or the efferent neurons in the ATP-evoked release of acetylcholine was 
further examined. 
In paper IV, the functional implications of the atropine-sensitive part of the 
purinergically-evoked response was examined in an in vivo whole bladder 
setup as well as an in vivo half bladder model. The half bladder setup enabled 
studies of afferent signalling and therefore the effects of the ATP-evoked non-
neuronal release acetylcholine on afferent nerve endings could be examined. 
The possible afferent modulatory effects of acetylcholine were further 
elucidated. 
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2 Materials and methods  
The experiments conducted in this doctoral thesis were approved by the 
Animal Ethics Committee in Gothenburg (approval numbers: 196-13 and 
1794/18). Male rats of the Sprague Dawley strain were used throughout the 
studies.  
All methods conducted in this thesis are described in detail in each paper. 2.1 Cyclophosphamide-induced cystitis 
Experimental cystitis was induced by a single intraperitoneal injection of CYP 
(100 mg/kg rat) and the rats were euthanized for experiment at the peak of 
inflammation (60 hours after the injection) (Giglio et al., 2005). 2.2 Removal of the urothelium 
Denudation of the urothelium was conducted by filling the bladders with 
collagenase I (0.1% in saline, 30 min). Urothelial cells were removed by gently 
massaging the bladder and then rinsing with saline. In addition, for bladder 
strip preparations, a cotton swab was used to detach urothelial cells. 2.3 In	vitro organ bath functional studies 
The rats were anesthetised and euthanized using an overdose of pentobarbital 
sodium (>60 mg/kg rat) and a subsequent incision through the heart. The 
urinary bladder was excised and kept in Krebs solution (CaCl2 1.25 mM, 
glucose 5.5 mM, KCl 4.6 mM, KH2PO4 1.15 mM, MgSO4 1.15 mM, NaCl 118 
mM and NaHCO3 25 mM) at all times. Subsequently, two full-thickness 
bladder strips (6 x 2 mm) excised proximal to the ureteral orifices and above 
the trigone were prepared. Alternatively, a whole bladder preparation was 
made in which two catheters were inserted via the urethral opening, for the 
administration of substances to the luminal side of the bladder and outflow 
respectively, and secured with threads.  
The bladder preparation was mounted in a 25 ml organ bath setup, between a 
fixed hook and an adjustable steel rod coupled to an isometric force transducer 
(Linton Instrumentation, Norfolk, UK). The organ baths were filled with Krebs 
solution kept at a temperature of 38 ▫C by a warm water circuit and at a constant 
pH of 7.4 by continuous gassing with 5% carbon dioxide in oxygen. The 
preparations were pre-stretched to 10-15 mN and left to equilibrate for 45 min, 
resulting in a basal tension of approximately 5 mN. High potassium Krebs 
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solution (124 mM, sodium exchanged for an equimolar amount of potassium) 
was used as a reference value for maximal contraction as well as a 
measurement of tissue viability throughout the experiments. Responses were 
recorded by AcqKnowledge software and a data acquisition system 
(MP100WSW; Biopac, Goleta, USA). 
The agonists and antagonists employed were either administered cumulatively 
into the organ bath in a volume of 125 µL (200 times the final concentration in 
the baths) or via the catheters (whole bladder setup) in a volume of 0.5 ml (at 
final concentration). All antagonists used were administered and let to 
equilibrate for 20 min before stimulation. The same was done for the 
neurotoxin tetrodotoxin (TTX).  
Electrical field stimulation (EFS; square wave pulses with a duration of 0.8 ms, 
delivered at supramaximal voltage) was applied at increasing frequencies (2, 
5, 10 20 and 40 Hz). 
When studying relaxatory responses, the tissue was pre-contracted using 
medium potassium Krebs solution (50 mM, sodium exchanged for an 
equimolar amount of potassium) for 20 min (until a stable pre-contraction) 
before the administration of pharmacological substances. 2.4 Immunohistochemistry 
Urinary bladders were collected and fixed in 4% paraformaldehyde (in 
phosphate buffered solution). After paraffin embedment, the tissue was 
sectioned into 8 µm thick segments (Histolab products AB, Gothenburg, 
Sweden). The tissue sections were deparaffinised, rehydrated and immersed in 
blocking solution (1 hour, 0.25% triton X, 25% normal goat serum in 
phosphate buffered saline) in order to prevent unspecific binding. After 
overnight incubation (room temperature) with primary antibodies, the sections 
were incubated with a secondary antibody for 2 hours. The sections were 
coverslipped with prolong gold antifade reagent (with DAPI, Life 
technologies, Eugene, OR) and viewed by microscopy (Eclipse 90i, Nikon, 
Tokyo, Japan).  2.5 Western blot 
The excised bladder was placed in homogenization-buffer (protease inhibitor 
cocktail, phosphatase inhibitor cocktail 2 in Hank’s buffered salt solution, 
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HBSS) and homogenized mechanically with a polytron (Ultra-Torax T8, 
IKA©-werke, Staufen in Breisgau, Germany) or by ultrasound in a Branson-
450-Sonifier (Branson ultrasonics, Danbury, USA). After centrifugation, 
protein quantification of the supernatant was performed using a Bio-Rad 
protein assay. 20 µg protein per well was loaded in a 10% w/v SDS gel for 
electrophoresis. After blotting to a nitrocellulose membrane (Thermo 
Scientific Rockford, IL, USA), the membrane was incubated in blocking 
solution (1 hour, using Blotting-Grade Blocker, Bio-Rad or non-fat dry milk, 
Semper) in order to prevent unspecific binding. Subsequently, the membrane 
was incubated with primary antibodies overnight (room temperature), washed 
in tris-buffered saline (0.1% Tween-20) and immersed in solution containing 
horseradish peroxidase-conjugated secondary antibodies for 2 hours. Finally, 
the membrane was incubated with ECL (a chemiluminescence system, 
ClarityTM Western ECL Substrate, Bio-Rad) for 5 min. The bands were 
visualized and quantified using a luminescence image analyzer (LAS-1000 
plus software, Image Reader LAS-1000 Pro, version 2.6, FUJIFILM, Tokyo, 
Japan). β-actin was used as reference for loading and normalization (for 
quantification) on stripped membranes (RestoreTM Western Blot Stripping 
Buffer, Thermo Scientific, Rockford, USA). 2.6 Nissl staining 
Excised urinary bladders were fixed in 4% paraformaldehyde (in phosphate 
buffered solution). The tissue was frozen and sectioned into 50-60 µm thick 
segments (Cryostat; Leica, CM1950; Leica Microsystems, Nussloch, 
Germany). Free floating segments were stained with cresyl violet acetate 
(0.2%), mounted and coverslipped with prolong gold antifade reagent (with 
DAPI, Life technologies, Eugene, OR) and viewed by microscopy (Eclipse 
90i, Nikon, Tokyo, Japan).  2.7 In	vivo whole bladder setup (cystometry) 
After induction of anaesthesia with isoflurane (1.5-2%), the rodent was placed 
on a heating pad connected to a rectal thermistor in order to monitor and keep 
the body temperature at a constant level of 38 °C. Adequate depth of 
anaesthesia was controlled by strong paw pinches which did not alter the heart 
rate or blood pressure. The femoral artery and vein were exposed via a small 
incision in the inguinal area followed by blunt dissection. After catheterization, 
the blood pressure was monitored via the femoral artery, whereas the venous 
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catheter was used for drug administration. After laparotomy, two catheters 
were inserted through the apex of the exposed bladder, one for intravesical 
administration of drugs and the other for internal pressure measurements (fig 
1; basal pressure between 10-15 mmHg). A ligature around the catheters and 
the bladder apex prevented leakage, which was validated through an 
intravesical administration of saline and subsequent voiding. The pelvic nerves 
were isolated in order to study responses in the intact, as well as denervated, 
bladder. 
 
Figure 1: Schematic representations of the whole bladder (A) and half bladder (B) in vivo 
models. In the whole bladder setup two catheters were inserted through the apex of the bladder, 
for the measurement of intravesical pressure and administration of drugs, respectively. In the 
half bladder setup, the ipsilateral bladder half (left in B) was used for modulating afferent 
signalling via stretch-induced responses and topical administration of drugs (white arrow). The 
contralateral bladder half was connected to a force transducer in order to register contractile 
responses. The pelvic nerves (at the base of the bladder in the illustration) were used for 
electrical nerve stimulation (B) or denervation (A, B). 
 2.8 In	vivo split-bladder setup 
The rat was prepared in the same manner as described for the cystometry setup. 
However, the bladder was prepared with two ligations at each side of the apex 
and at each side of the bladder, as well as at each side of the urethra below the 
pelvic nerves. The bladder was then completely separated into two halves (fig 
1). The ligatures at the sides of the urethra and the bladder were fixed to the 
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underlying tissue. The contralateral bladder half apex was then connected to 
an isometric force transducer (Linton Instrumentation, Norfolk, UK) coupled 
to a computer system (MP100WSW data acquisition system and 
AcqKnowledge software). The other half (ipsilateral) was used for initiating 
afferent signalling via topical administration of substances (to the luminal side 
of the bladder) or stretch-induced responses, using weights of 8 g. Topical 
administration to the contralateral bladder half enabled the study of responses 
without activation of the micturition reflex arc. The pelvic nerve on the 
ipsilateral side of the bladder base was placed on a bipolar platinum electrode, 
enabling afferent stimulation (20 Hz, at supramaximal voltage, square wave 
pulses with a duration of 0.8 ms), and contractile responses were measured 
from the contralateral bladder half. An afferent stimulation was confirmed by 
the absence of contractile responses during deep anaesthesia when reflexive 
responses are silent. Reflexive responses were usually observed at an 
isoflurane level of 1-1.2%. Adequate depth of anaesthesia was controlled by 
strong paw pinches which did not alter the heart rate or blood pressure. A 
detailed description of this novel in situ half bladder preparation enabling 
afferent stimulation has been published previously (Aronsson et al., 2014a). 2.9 Statistical analysis 
The in vitro and in vivo functional studies were analysed using repeated 
measurement ANOVA (for multiple comparisons of the same variable) 
followed by the Bonferroni post-hoc test or Student’s t-test when comparing 
two groups. For the western blots, the densities of the bands were analysed by 
Mann Whitney’s test or Wilcoxon sign test. The result was described as mean 
± S.E.M, p-values less than 0.05 were regarded as statistically significant. The 
GraphPad Prism software was used to generate the graphs and parameters 
presented (GraphPad Software Inc., San Diego, USA). 2.10 Materials 
All substances were purchased from Sigma-Aldrich, St Louis, MO, unless 
otherwise stated. 2.10.1 Cholinergic and purinergic substances 
5’-(N-ethylcarboxamido)adenosine (NECA, Tocris Bioscience, Bristol, 
United Kingdom), α,β-methylene adenosine 5’-triphosphate (α,β-MeATP, 
Tocris Bioscience, Bristol, United Kingdom), acetyl-β-methylcholine 
(methacholine), adenosine 5’-diphosphate (ADP), adenosine 5’-triphosphate 
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(ATP), atropine, methoctramine, N,N”-1,4-butanediylbis[N’-(3-
isothiocyanatophenyl)]thio urea (MRS 2578, Tocris Bioscience, Bristol, 
United Kingdom), pirenzepine, pyridoxal-phosphate-6-azophenyl-2’,4’-
disulphonic acid (PPADS), suramin. 2.10.2 Other substances 
CaCl2, citric acid, collagenase type 1 (Invitrogen, Paisley, United Kingdom), 
cyclophosphamide monohydrate (CYP), dimethyl sulfoxide (DMSO), ethanol 
(Kemetyl, Stockholm, Sweden) glucose, HCl, heparin (Leo Pharma, Ballerup, 
Denmark), KCl, KH2PO4, methanol, methyl-β-cyclodextrine (Me-β-CD), 
MgSO4, NaCl, NaHCO3, NaOH, pentobarbitone sodium (Pentobarbitalnatrium 
vet.; APL, Stockholm, Sweden), sucrose, tetrodotoxin (TTX, Tocris 
Bioscience, Bristol, United Kingdom), triton X, tris, tween-20, xylene 
(Kemetyl, Stockholm, Sweden). 2.10.3 Reagents and solutions for Immunohistochemistry and western blot 
Alexa Fluor 488 goat anti-rabbit IgG (Thermo Scientific, Rockford, IL, USA), 
anti-caveolin-1 (ab2910, Abcam, Cambridge, United Kingdom), anti-choline-
acetyltranseferase (ChAT, ab178850, Abcam, Cambridge, United Kingdom), 
anti-carnitine-acetyltransferase (CarAT, PAC400Ra01, Clone Corporation, 
Houston, TX, USA), β-actin (SC-47778, Santa Cruz Biotechnology, Dallas, 
TX, USA), blotting-Grade Blocker (Bio-Rad), cresyl violet acetate, 
horseradish peroxidise-conjugated goat anti-mouse (62-6520, Thermo 
Scientific, Rockford, IL, USA), horseradish peroxidise-conjugated goat anti-
rabbit (65-6120, Thermo Scientific, Rockford, IL, USA), normal goat serum 
(NGS; Vector Laboratories, Burlingame, Canada), ECL (Clarity TM Western 
ECL Substrate, Bio-Rad), phosphate buffered saline tablets (PBS; Thermo 
Scientific, Rockford, IL, USA), PierceTM BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL, USA), paraformaldehyde, phosphatase inhibitor 
cocktail 2, prolong gold antifade reagent with DAPI (Thermo Scientific, 
Rockford, IL, USA), protease inhibitor cocktail, stripping buffer (Western Blot 
Stripping Buffer, Thermo Scientific, Rockford, IL, USA). 
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3 Results and Discussion 
Crosstalk between different transmitter systems are common in the lower 
urinary tract and may occur at various levels of the micturition reflex arc. In 
this thesis, one such interaction between the two important parasympathetic 
transmitter substances ATP and acetylcholine has been identified and its 
functional implications have been characterized using different in vitro and in 
vivo methods. Furthermore, the role of functional structures such as the 
urothelium and the caveolae in this link has been elucidated. Finally, a role for 
acetylcholine in activating the micturition reflex arc on its own has been 
identified in vivo.  3.1 Atropine-sensitive purinergic functional responses 
The present results support the hypothesis of an ATP-induced release of 
acetylcholine with functional implications to exist in the rat urinary bladder, 
both in vitro and in vivo. This was made evident by a significant reduction in 
purinergic contractile responses in the presence of the non-selective muscarinic 
antagonist atropine. The reduction in contractile response was similar 
throughout the different setups used (i.e. in vitro organ bath and the in vivo 
whole bladder or split-bladder model; table 1), indicating approximately half 
of the ATP-evoked responses to depend on a subsequent release of 
acetylcholine (papers I and IV; fig 2).  
 
Table 1: Reduction (%) of ATP-evoked contractile responses in the presence of atropine in 
different in vitro and in vivo models. In experiments where more than one concentration of ATP 
was administered the values from the highest concentration of ATP have been included. 
Experimental setup Reduction in purinergic contraction in 
the presence of atropine 
In vitro (strip preparation; paper II) 65% 
In vitro (whole bladder; paper I) 50% 
In vivo (denervated whole bladder;  
paper IV) 
43% 
In vivo (split bladder, topical administration 
to the contralateral bladder half; paper IV) 
39% 
In vivo (denervated split bladder, i.v. 
administration of ATP, paper IV) 
47% 
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Signs of this functional interaction between ATP and acetylcholine, where 
ATP induces a release of acetylcholine directly affecting the contractile 
response of the detrusor muscle, have previously been presented both in vitro 
and in vivo (Aronsson et al., 2014a; Sjogren & Andersson, 1979). However, 
neither the origin of the cholinergic part of ATP-evoked responses in the 
urinary bladder, the receptors involved in functional responses, nor functional 
implications beyond direct smooth muscle contraction have been addressed.  
 
Figure 2: Mean contractile responses to ATP in whole bladder preparations in vitro (A; 
adapted from paper I) and in vivo (B; adapted from paper IV), before and after the administration 
of atropine. In vivo (B), the effects of atropine on purinergic contraction were examined after 
pelvic nerve denervation. p<0.05 is denoted by * when compared to ATP, and # when compared 
to denervated bladder preparations, respectively. n=13 in vitro and n=6 in vivo. The vertical bars 
represent S.E.M.  
 3.1.1 Urothelial involvement 
The urothelium with its sensory properties is a likely source for the ATP-
induced release of acetylcholine and it is involved in a variety of other such 
interactions. For instance the stimulation of muscarinic urothelial receptors 
may induce the release of NO from the urothelium (Andersson et al., 2008). In 
this thesis the expressions of the acetylcholine synthesising enzymes ChAT 
and CarAT were investigated, and both enzymes were found to be present in 
rat urinary bladder tissue. CarAT has previously been suggested to be the main 
enzyme responsible for non-neuronal synthesis of acetylcholine (Hanna-
Mitchell et al., 2007; Yoshida et al., 2008). 
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Notably, it has previously been observed in (non-functional) transmitter 
release studies, that an ATP-induced release of acetylcholine from the 
urothelium may exist (Hanna-Mitchell et al., 2007; Silva et al., 2015). This 
non-neuronal release of acetylcholine could potentially act either directly on 
the muscarinic receptors on the smooth muscle, or have paracrine actions 
stimulating the release of other neurotransmitters from the urothelium or 
suburothelium.  
3.1.1.1 In	vitro	
An in vitro whole bladder setup (see Methods and Material, section: 2.7), 
enabling site-specific administration to the luminal or adventitial side of the 
bladder respectively, was used in order to determine whether or not the 
presumable link between ATP and acetylcholine could be activated from both 
sides (paper I). The results showed an atropine-sensitive component to be up 
to half of the functional contraction to intravesically administrated ATP; i.e. 
from tissue that was not accessible from the adventitial side of the bladder wall. 
Atropine did not affect ATP-induced responses when administered to the 
external side of the bladder, which favoured the idea of a urothelial origin for 
the cholinergic part of ATP-evoked responses. Urothelial removal 
(denudation) using collagenase I was used in order to confirm this (papers I-II 
and IV). Indeed, urothelial denudation eliminated the atropine-sensitive part of 
the ATP-evoked responses in vitro, strongly indicating the cholinergic part of 
these responses to emanate from the transitional epithelium (fig 3a).  
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Figure 3: Mean contractile responses to ATP in urothelium-denuded whole bladder 
preparations in vitro (A; adapted from paper I) and in vivo (B; adapted from paper IV), before 
and after the administration of atropine. In vivo (B) the effects of atropine were examined after 
pelvic nerve denervation. In vitro experiments (A) include a control administration of ATP 
before urothelial denudation (open symbol). * indicates p<0.05, n=8 in vitro and n=5 in vivo. 
The vertical bars represent S.E.M. 
3.1.1.2 In	vivo	
In accordance with the findings in vitro, denudation of the urothelium in the in 
vivo whole bladder setup more or less removed the ATP-evoked release of 
acetylcholine (fig 3b). Furthermore, in intact bladders, denervation of the 
bladder significantly decreased the purinergic response, suggesting an effect 
on afferent signalling in addition to any direct detrusor stimulation. This 
observation was absent in urothelium-denuded preparations, highlighting the 
importance of an intact urothelium for healthy bladder signalling as both the 
sensory signalling and direct muscle contraction seem to be impaired in 
denuded preparations.  3.1.2 Neuronal involvement 
Despite the clear evidence for a urothelial origin of the ATP-evoked release of 
acetylcholine presently observed (paper I, II and IV; see section: 3.1.1) a 
plausible neuronal origin ought to be examined. Hence, the effects of the potent 
neurotoxin TTX on this functional interaction was examined in vitro. 
Methacholine-induced responses were used as control and the ability of TTX 
to abolish efferent nerve signalling was confirmed by EFS. Similar to previous 
studies ATP- and acetylcholine-evoked responses remained unchanged in the 
presence of TTX, suggesting their main site of action in vitro to be directly on 
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the smooth muscle and/or on the urothelium/suburothelium (Aronsson et al., 
2010; McMurray et al., 1998). Furthermore, the ATP-evoked release of 
acetylcholine was shown to be TTX-insensitive as atropine still caused a 
significant decrease of 60% in purinergic response when subjected to the 
neurotoxin. As expected, the effects of atropine on cholinergic stimulation 
were TTX-insensitive as well. These results favour the idea of a urothelial, 
rather than neuronal, origin of the cholinergic part of the ATP-evoked 
responses presently investigated. 3.1.3 Characterization of involved receptors 
3.1.3.1 Functional	contractile	responses	
In order to characterize the purinoceptor subtypes mediating the purinergic-
cholinergic interaction described above, a range of purinergic agonists and 
antagonists with different receptor profiles were applied in vitro (paper III). To 
characterize any involvement of the P2X-purinoceptors in the non-neuronal 
release of acetylcholine α,β-MeATP was employed. This substance is a stable 
ATP-analogue, generally regarded to mainly stimulate the P2X1- and P2X3-
purinoceptors when administered in single concentration-response 
experiments (Ralevic & Burnstock, 1998). When administered repeatedly in 
high concentrations the response is, however, markedly lowered and the 
substance instead acts as a desensitizer at the same receptors. The plausible 
sensitivity of α,β-MeATP towards atropine was examined (paper III). 
Interestingly, similar to the ATP-evoked contractions, the purinergic 
contractile response to α,β-MeATP (administered as an agonist) was 
significantly reduced by a third in the presence of atropine. These observations 
give support to the supposition that it is ATP, rather than any of its metabolites, 
which mediates the cholinergic interaction. It is suggested that the P2X-
purinoceptors, most likely of the P2X1- or P2X3-subtype, are responsible for 
stimulating the release of non-neuronal acetylcholine in vitro in the rat bladder. 
(Control experiment with repeated administrations of α,β-MeATP were 
performed in order to exclude these effects to depend on desensitization of the 
purinoceptors, which could be ruled out.) 
Another receptor subtype candidate recently suggested to facilitate release of 
urothelial non-neuronal acetylcholine is the P2Y6-purinoceptor (Silva et al., 
2015). It has, however, not been evaluated whether or not this proposed 
mechanism constitutes a functionally important one in the rat urinary bladder, 
i.e. if the P2Y6-purinoceptor is able to release acetylcholine to such an extent 
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that it triggers smooth muscle contraction or if other purinoceptor-subtypes are 
dominating. Direct purinergic responses can further depend either on ATP 
stimulating (mainly) P2X-purinoceptors, or metabolites of ATP, such as ADP 
and adenosine, acting on P2Y- or P1-purinoceptors, respectively. Hence, the 
effects of MRS2578, a P2Y6-antagonist, on the ATP-evoked release of 
acetylcholine was examined. However, as the present results indicate the ATP-
evoked contractile responses still to be sensitive towards atropine regardless of 
the presence of MRS2578 (a significant reduction by 48%), there is currently 
no support for this purinoceptor to be involved in the ATP-induced release of 
acetylcholine; at least not to such an extent that the subsequent release alone 
evokes smooth muscle contraction. 
3.1.3.2 Functional	relaxatory	responses	
The plausible involvement of acetylcholine in relaxatory purinergic responses 
was examined in an in vitro organ bath setup (paper III). Desensitization of the 
P2X-purinoceptors, using repeated additions of α,β-MeATP, did not affect the 
ATP-induced relaxatory responses in pre-contracted tissue, indicating the 
ATP-evoked relaxatory responses of the detrusor muscle to be dependent on 
P2Y-purinoceptors. Neither the subsequent administration of atropine, nor the 
addition of PPADS followed by atropine altered the relaxatory responses to 
ATP. These results suggest the ATP-induced relaxatory component to be 
independent of the P2X-purinoceptors as well as any ATP-evoked release of 
acetylcholine in vitro. However, in the bladder also the metabolites to ATP 
may elicit relaxation of the detrusor smooth muscle. Hence, the sensitivity of 
relaxations to ADP or NECA (an adenosine analogue) towards atropine was 
examined, however no significant effects of atropine were observed for these 
substances. 
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3.1.4 Changes in experimental cystitis  
Bladder inflammation, often present during disorders such as BPS/IC and 
sometimes OAB, has been shown to affect cholinergic as well as purinergic 
signalling (McDermott et al., 2013; Sun et al., 2001). For instance, both 
acetylcholine and ATP are released during stretch of the urothelium, and the 
released amount is elevated during inflammation (McDermott et al., 2013; Sun 
et al., 2001). Furthermore, the cholinergic contractile response is reduced 
during experimentally induced cystitis (Giglio et al., 2005; Mok et al., 2000). 
Therefore, the functional interaction between ATP and acetylcholine was 
examined in rats with CYP-induced cystitis (paper I-II). Generally, ATP and 
methacholine evoked concentration dependent contractile responses that were 
reduced in CYP-pre-treated animals (by up to approximately two thirds for 
ATP in paper I). Interestingly, while atropine still caused a significant decrease 
in cholinergic responses in cystitic bladders, the ATP-evoked contractile 
response was, unlike the findings in healthy controls, not significantly affected 
by atropine (fig 4). Similarly, removal of the urothelium did not significantly 
alter the purinergic responses in bladders from CYP-pre-treated rats (fig 4). 
The same phenomenon was observed regardless of administration order; i.e. 
atropine being added before denudation or vice versa. These results indicate an 
alteration in the urothelium dependent non-neuronal cholinergic component of 
the purinergic response in cystitis.  
Figure 4: Mean contractile responses to ATP in cystitic intact and urothelium-denuded 
whole bladder preparations (adapted from paper I) in the absence and presence of atropine in 
vitro. Re-administration of ATP in the presence of atropine was either performed before (A; 
light grey symbol) or after (B; black symbol) the removal of the urothelium. n=7-8 for each 
group. The vertical bars represent S.E.M.  
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In order to unravel the mechanism responsible for the changes in non-neuronal 
acetylcholine signalling, the expressions of ChAT and CarAT in cystitis were 
semi-quantified using western blot (paper I). Alterations in the activity or 
quantity of these enzymes during cystitis could have explained the changes in 
contractile response currently observed. However, no significant alterations in 
the expression of the acetylcholine-synthesising enzymes could be found in the 
cystitic bladders when compared to healthy controls, although a slight 
indication towards a reduced quantity of CarAT could be seen. Nonetheless, 
complicating factors such as degradation products and various isoforms need 
to be taken into consideration when interpreting these results. Regardless, other 
possible explanations for the reduced release of non-neuronal acetylcholine 
exists, such as alterations in VAChT or OCT activity. Nonetheless, the present 
results highlight the important and complex properties of the urothelium for 
healthy bladder function. 3.2 Functional roles of caveolae in urinary bladder signalling 
Another structure often considered important in bladder signalling are the 
caveolae. These caveolin-containing lipid-rafts have been shown to be vital for 
healthy bladder signalling due to their ability to function as signalling 
platforms (Lisanti et al., 1994; Shaul & Anderson, 1998). Consequently, 
caveolin-1 knockout mice express an impaired ability to elicit normal smooth 
muscle contraction (Sadegh et al., 2011). Caveolae have also been accredited 
other functional roles such as endocytosis (Parton & Simons, 2007). During 
pathological bladder conditions such as detrusor overactivity, the caveolae-
mediated signalling appears to be altered due to a change in caveolae density 
(Cristofaro et al., 2012). In this thesis, the plausible involvement of caveolae-
dependent signalling for the ATP-evoked release of acetylcholine was 
examined. Furthermore, changes in caveolae-mediated signalling during 
experimentally induced cystitis was characterized in vitro (paper II). 3.2.1 Changes in response to caveolae depletion 
Presently, any caveolae-mediated signalling was identified by experimental 
removal of the caveolae lipid rafts by incubation of the tissue with Me-β-CD, 
interrupting the cholesterol structures in the caveolae membranes (Dreja et al., 
2002; Shakirova et al., 2010). Previous studies using this technique have 
reported a disruption of caveolae without altering other morphological 
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structures of the smooth muscle (Cristofaro et al., 2007; Shakirova et al., 2010). 
This is supported by the lack of effect of Me-β-CD-treatment on the general 
contractile ability of the tissue elicited by high potassium Krebs solution (124 
mM), as well as the intact responses to muscarinic stimulation currently 
observed. However, one should bear in mind that it seems feasible that 
Me-β-CD could target also other lipid rafts.  
In control bladders, incubation with Me-β-CD significantly decreased the 
purinergic, but not cholinergic contractions to exogenously administered 
agonists in vitro by 61%. Thus, the purinergic signalling is likely, at least to 
some extent, to be depending on intact caveolae. It was further shown that a 
part (69%) of the EFS-evoked contractile response was also affected by 
depletion of the caveolae, suggesting neuronally released transmitters to be 
dependent on caveolar structures. EFS-evoked responses can be described as a 
transient phasic component followed by a slower tonic contraction (Brading & 
Williams, 1990). The phasic component has a shorter duration (0.5-1.5 sec. in 
this thesis, paper II) and is usually accredited to the stimulation of 
purinoceptors. The tonic component on the other hand corresponds mainly to 
cholinergic responses. Hence, in order to examine the effects of caveolae-
depletion on neuronally released ATP and acetylcholine the phasic and tonic 
components of the EFS-evoked responses were analysed (paper II). The results 
indicated both the phasic and tonic components to be partly caveolae-
dependent, where reductions to caveolae depletion by 59% and 87% were seen 
in the phasic and tonic components, respectively. This suggests a difference in 
response to exogenously administered methacholine and neuronally released 
acetylcholine. This may seem contradictive at first, however the difference 
might be explained by other substances than ATP and acetylcholine being 
released during EFS.  3.2.2 Changes in experimental cystitis  
In bladders from CYP-pre-treated animals, incubation with Me-β-CD did not 
significantly alter the contractile responses to exogenously administered ATP 
or methacholine. Likewise, the EFS-induced responses were insensitive to 
caveolae-depletion in cystitic bladders. This could possibly be explained by an 
altered expression of caveolae. Hence, expression of caveolin-1, the protein 
required for caveolae formation, was analysed by western blotting as well as 
immunohistochemistry. The results indicated a lowered expression of 
caveolin-1 in cystitic bladders, which in turn is an indirect indication of a 
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decreased amount of caveolae in the tissue sample. Similar reductions in 
caveolin-1 expression during CYP-induced cystitis have been presented 
previously, supporting the current result (Kim et al., 2012). 3.2.3 A link between the caveolae and urothelium important to atropine-sensitive purinergic responses  
As mentioned above, caveolae-depletion significantly decreased the ATP-
evoked responses in healthy controls. Notably, the atropine-sensitive part of 
ATP-evoked responses was of a similar magnitude and incubation with 
Me-β-CD removed this cholinergic part of the ATP-evoked responses (fig 5), 
which indicates the ATP-induced release of acetylcholine to be caveolae-
dependent. However, based on our previous findings this interaction is also 
dependent on the urothelium (paper I). Hence, a possible interplay between the 
caveolae and the urothelium was investigated by removal of either structure. 
A profound interaction was identified where purinergic contractile responses 
in caveolae depleted bladders were not significantly affected by the subsequent 
urothelial denudation. Similarly, in denuded preparations no further reduction 
in purinergic response could be observed after the administration of Me-β-CD.  
 
Figure 5: Impact of caveolae depletion on in vitro purinergic contractions (adapted from 
paper II) in control bladder strip preparations. Mean contractile responses to ATP in the absence 
and presence of atropine, before and after caveolae depletion. * denotes p<0.05, n=5. The 
vertical bars represent S.E.M. 
Functional studies of purinergic and cholinergic interactions in the rat urinary bladder 
 
34 
This interaction between the caveolae-mediated signalling and the signalling 
mediated by the urothelium is probably of fundamental importance for the 
ATP-evoked release of acetylcholine based on the observation that the 
disruption of either structure removes the atropine sensitivity of purinoceptor-
mediated responses. The present findings might even suggest these caveolae 
to be located on the urothelium. 
To summarize, the caveolae seem to be important for purinergic signalling in 
the healthy rat urinary bladder. Furthermore, as indicated by the effect of 
Me-β-CD on the phasic component of the EFS-evoked responses and the 
effects on the cholinergic part of the ATP-induced responses, two caveolae-
dependent pathways for ATP-appear to exist, affecting the neuronal ATP 
signalling and the ATP-evoked release of acetylcholine respectively. 
A functional interplay appear to exist between the urothelium and the caveolae, 
important for the atropine-sensitive part of the ATP-evoked contractile 
responses. Furthermore, cystitis seems to alter caveolae-mediated signalling, 
including the functional link between ATP and the urothelial release of 
acetylcholine.  3.3 Afferent and efferent modulation in	situ  
In this thesis so far, the ATP-evoked release of acetylcholine has been 
identified and functional implications such as direct detrusor smooth muscle 
contraction without any involvement of the micturition reflex arc have been 
established. However, this urothelial release of acetylcholine may stimulate 
afferent and/or efferent nerve endings as well. Cholinergic modulation of 
bladder c-fibres have previously been suggested, even though direct evidence 
has yet to be presented (Kullmann et al., 2008). 
ATP has many roles in the micturition reflex arc and even though the 
purinergic contribution to direct detrusor contraction appears to be minor in 
healthy humans, ATP may have paracrine effects and is regarded to be an 
important mediator for afferent signalling (Cockayne et al., 2005; Cockayne et 
al., 2000; Silva et al., 2015). Part of the afferent signalling has been shown to 
be mediated through the stretch-induced release of ATP acting on afferent 
P2X2-, P2X3- and/or P2X2/3-purinoceptors (Cockayne et al., 2005). In light 
of the many purinoceptors being expressed in the urothelium and the range of 
substances being released, ATP may also exhibit paracrine effects on the 
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urothelium inducing the release of other substances that may influence 
signalling (Birder & Andersson, 2013; Birder et al., 2004; Elneil et al., 2001; 
Shabir et al., 2013).  
In order to examine afferent and efferent contributions, an in vivo whole 
bladder setup as well as a half bladder model, requiring signals to travel via the 
CNS in order to elicit any response, were employed (paper IV).  3.3.1 Purinergic and cholinergic interplay on afferent signalling 
Similar to the observations in the whole bladder model, the ATP-evoked 
responses (intravenous, i.v. administration) in the half bladder setup was 
significantly reduced by about a third in the presence of atropine. Furthermore, 
topical administration of ATP (ipsilaterally; i.e. on the opposite side of 
contractile measurement) triggered the afferents of the micturition reflex arc 
resulting in dose-dependent contractile responses of the contralateral bladder 
half. This is not a novel phenomenon as ATP is known to be important for the 
initiation of the micturition reflex arc via the stimulation of purinoceptors on 
the afferent neurons (Cockayne et al., 2005). However, after the topical 
administration of atropine (ipsilaterally), a significant decrease by 27% in the 
ATP-induced activation of the reflex arc was observed. This indicates the 
cholinergic part of ATP-evoked responses to be able to activate afferent nerve 
fibres. 
A role for non-neuronal acetylcholine in the micturition reflex arc has 
previously been suggested, for instance based on findings in OAB-patients 
where anticholinergic treatment appears to elicit its effects also during the 
storage phase of micturition, where no parasympathetic efferent release is 
thought to occur (Andersson, 2011; Yokoyama et al., 2005). The present 
finding that a significant part of the ATP-induced activation of the micturition 
reflex arc is dependent on a non-neuronal release of acetylcholine suggests 
acetylcholine to be able to initiate the micturition reflex arc on its own. This 
was further investigated by topical administration of methacholine on the 
ipsilateral bladder half, which resulted in a contraction of the contralateral side, 
confirming the hypothesis that acetylcholine may activate reflex responses in 
itself. However, acetylcholine is a potent paracrine modulator and is known to 
stimulate the release of other neurotransmitters from the urothelium. One such 
substance is ATP - known to be important for the initiation of the micturition 
reflex arc. Therefore, the effects of PPADS on methacholine-induced reflex 
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responses was examined. Indeed, a significant part of the functional response 
to methacholine-evoked activation of bladder afferents was lowered (by 26%) 
by the administration of PPADS, and was thus considered to be dependent on 
the release of ATP. However, a substantial part of the methacholine-induced 
afferent signalling remained intact, suggesting a direct effect of acetylcholine 
on afferent nerve endings to exist. Lastly, stretch-induced responses were 
significantly reduced in the presence of atropine and PPADS, where PPADS 
gave rise to twice the reduction compared to atropine in response to ipsilateral 
stretch, suggesting both transmitters to be involved in afferent signalling.  3.3.2 Acetylcholine and afferent modulation 
As shown in the previous section, not only purinergic receptors are expressed 
on afferent neurons, other receptors including muscarinic-receptors are 
expressed as well (Nandigama et al., 2010; Yoshimura et al., 2001). 
Specifically, the M2, M4 and M3-receptors have been identified on afferent 
neurons in the mouse bladder (Nandigama et al., 2010). Furthermore, the M1- 
and M2-receptors are known to affect neuronal acetylcholine release (Somogyi 
et al., 1994; Tobin, 1998). In order to characterize any modulatory role for 
muscarinic receptors in the micturition reflex arc of the rat urinary bladder, the 
effects of methoctramine (a selective antagonist affecting the M2/M4-subtypes) 
and pirenzepine (a selective antagonist affecting the M1-subtype) on stretch-
induced, as well as ATP-induced, reflex responses were examined in the half 
bladder model. No effect of the administration of the M1-antagonist was 
observed, instead indicating the muscarinic M3-subtype to be responsible for 
the stimulation of afferent nerve fibres in this model. However, methoctramine 
significantly increased the contralateral contractions induced by ipsilateral 
stretch as well as local ATP administration to the ipsilateral bladder half, where 
the increase in response to ATP was half of the increase in response to stretch. 
These observations indicate a muscarinic modulation of afferent signalling to 
occur either directly on the bladder afferents, or indirectly via the urothelium. 
Examinations of the effects of methoctramine on ATP-induced contractile 
responses in the in vitro organ bath setup revealed no interaction between these 
substances, suggesting the cholinergic inhibitory modulation to occur via 
M2/M4-receptors situated directly on the sensory neurons in the rat urinary 
bladder. 
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4 Concluding remarks 
A substantial part of ATP-evoked contractile responses in the rat urinary 
bladder depends on the urothelial release of acetylcholine, as demonstrated by 
the present results. This thesis aimed to characterize the plausible functional 
implications of this link on the various levels of the micturition reflex arc. By 
using several in vitro and in vivo techniques, strong evidence for a cholinergic 
part, supporting the purinergic functional contractions, has been presented. 
Furthermore, receptor characterization using various agonists and antagonists 
indicated the release of acetylcholine to, most likely, be mediated via urothelial 
P2X1- and/or P2X3-purinoceptors. Regarding functional implications, 
observations in vitro as well as in the denervated bladder in vivo showed the 
ATP-evoked release of acetylcholine to be able to stimulate direct smooth 
muscle contraction also independent of the micturition reflex arc.  
The hypothesis that the urothelium is the source for ATP-evoked release of 
acetylcholine was investigated. This was confirmed to be the case by urothelial 
removal, which eradicated the functional ATP-evoked release of acetylcholine 
both in vitro and in vivo. Notably, when disrupting the pelvic innervation in 
vivo (whole bladder setup) a significant decrease in the purinergic contractile 
response was observed, suggesting the removal of afferent reflex responses. 
This activation of afferent signalling was not present in urothelial denuded 
animals, highlighting the importance of an undamaged urothelium for healthy 
bladder signalling. Furthermore, based on the current findings, using the 
neurotoxin TTX, no direct efferent neuronal involvement could be identified, 
further supporting the theory of a urothelial origin.  
In healthy animals, both the phasic component of the EFS-induced responses 
(tentatively indicating the neuronal release of ATP) and the ATP-induced 
release of acetylcholine were shown to be caveolae-dependent. The current 
results also identified a functional interaction between the urothelium and the 
caveolae. This may be interpreted as urothelial caveolae being mainly 
responsible for the purinergic-cholinergic link presently investigated. This, 
however, remains to be fully proven. 
This thesis further elucidated the effects of experimentally induced cystitis on 
the ATP-evoked release of acetylcholine in vitro. Interestingly, this functional 
interaction was hindered by inflammation, indicating that cystitis affects the 
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urothelium in such a way that the non-neuronal synthesis of acetylcholine is 
significantly altered.  
Finally, the ATP-induced release of acetylcholine, as well as direct cholinergic 
activation, was shown to be able to stimulate afferent nerve fibres, triggering 
the activation of the micturition reflex arc. The cholinergic modulation was 
shown to depend on the stimulation of facilitatory M3- and inhibitory M2/M4-
receptors. Many of the LUTS present in pathological bladder disorders, 
including OAB and BPS/IC, are thought to occur due to an alteration in sensory 
signalling. ATP is known to be able to initiate afferent signalling and afferent 
purinoceptors are often discussed as potential targets in the development of 
new drugs for LUTS. The novel findings in this thesis suggest that the ATP-
evoked non-neuronal release of acetylcholine can modulate bladder afferent 
activity. This may in turn provide new insights for drug development as well 
as an increased knowledge of healthy bladder signalling. 4.1 Conclusion 
This thesis identifies an ATP-evoked release of urothelial acetylcholine, most 
likely via the stimulation of the P2X1- and/or P2X3-subtype, which largely 
contributes to ATP-induced effects in the rat urinary bladder. The release of 
non-neuronal acetylcholine directly affects smooth muscle contraction as well 
as afferent nerve signalling. Cystitis seems to alter the urothelial non-neuronal 
signalling in such a way that the ATP-evoked release of acetylcholine 
diminishes, highlighting the importance of an intact urothelium and caveolae 
for normal bladder function. 
Furthermore, ATP-induced release of acetylcholine was proven able to 
modulate reflex responses on its own via the stimulation of M2/M4 and M3-
receptors, providing new insights for bladder afferent signalling which might 
be relevant for the altered sensory signalling observed in OAB- and BPS/IC-
patients. 
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